Half-year report · HY
2934.TEDINET S100XFQN
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.7bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥21.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.8bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | −¥143m | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥27m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | −¥132m | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥232m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | −¥176m | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥191m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥88m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥21m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥187m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | −¥5m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥9.9bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥9.2bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.8bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥7.2bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.0bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥103m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥509m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥13m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥924m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥471m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥220m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥722m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥623m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥139m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-36.36 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.42 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.32 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥17.21 | 2024-06-01 → 2025-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 14.2% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 15.3% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-06-01 → 2025-11-30 | −¥37m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-06-01 → 2025-11-30 | −¥37m |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2025-11-30 | −¥212m |
| Healthcare Marketing Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥5.3bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥5.3bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥20m |
| Healthcare Marketing Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥83m |
| Healthcare Sales Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥2.8bn |
| Healthcare Sales Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥2.8bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥14m |
| Healthcare Sales Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | −¥122m |
| Medical Care Sales Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥2.6bn |
| Medical Care Sales Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥2.6bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| Medical Care Sales Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥108m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2025-11-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2025-11-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥37m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2025-11-30 | ¥69m |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥180m |
| Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.7bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.6bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥96m |
| Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥24m |
| Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥11m |
| Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥4m |
| Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥2m |
| Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥236m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥109m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥207m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 547
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 1000000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.1875 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 253300 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0475 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 153900 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0289 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 153135 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0287 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 85300 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0160 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 59000 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0111 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 53135 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0100 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 49000 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0092 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 41000 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0077 | |
| Number of shares held | InterimInstant | 4216770 | |
| Shareholding ratio | InterimInstant | 0.7906 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 5330100 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 53301 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 3365 | |
| Number of shares issued shares voting rights | InterimInstant | 5333465 | |
| Number of voting rights issued shares voting rights | InterimInstant | 53301 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | － | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | － | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | － | |
| Number of shares held in own name treasury shares etc | InterimInstant | － | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | － | |
| Shareholding ratio treasury shares etc | InterimInstant | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 100000 | |
| Number of male directors and other officers | FilingDateInstant | 9 | |
| Number of female directors and other officers | FilingDateInstant | － | |
| Ratio of female directors and other officers | FilingDateInstant | － | |
| Cash and deposits | Prior1YearInstant | 2169645000 | JPY |
| Cash and deposits | InterimInstant | 2067333000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 1247878000 | JPY |
| Accounts receivable trade | InterimInstant | 1356510000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 1620575000 | JPY |
| Merchandise and finished goods | InterimInstant | 1618363000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 125344000 | JPY |
| Raw materials and supplies | InterimInstant | 139679000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |